Shares of Brazilian oncology services provider Oncoclínicas (ONCO3) surged 36.5% on Monday to R$1.57, after the company completed the sale of a 27.49% stake in its Saudi Arabian joint venture for US$6.55 million (R$33.3 million).
The transaction, disclosed after market close on August 20, followed the release of the company’s second-quarter 2026 results on August 17. Oncoclínicas reported a net loss of R$275 million for the quarter, reflecting ongoing pressures from a medicine supply crisis, but its adjusted EBITDA turned positive at R$34.3 million, signaling early signs of operational stabilization.
The rally was further supported by a court-approved extrajudicial recovery plan on August 4, which granted the company a 180-day stay on creditor actions. The plan also prohibited health insurance operators from revoking the company’s credentials, reducing near-term operational risks. Proceeds from the Saudi stake sale are earmarked for purchasing medications under the restructuring framework.
The São Paulo-listed stock traded between R$1.25 and R$1.75 during the session, with the broader Ibovespa index rising 1.85% to extend a three-day winning streak. Analysts noted the sale proceeds and legal protections as key catalysts for the sharp advance, which was characterized as a short-covering rally driven by restructuring progress and early EBITDA recovery.
The company’s shares remain well below their 52-week high of R$3.91, reflecting lingering concerns over liquidity and operational challenges despite the recent improvements.
